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Abstract
Pharmacological treatment of migraine includes acute and, in some patients, preventive medications.
Here, the most relevant recent advances in migraine management are reviewed. Regarding acute
treatment, new data indicate that early treatment of migraine attacks should be recommended to
those patients who do not show a clear response when pain is already moderate or severe. It has also
been shown that, in terms of efficacy, the combination of a nonsteroidal anti-inflammatory drug plus a
triptan is superior to monotherapy. In the immediate future it seems that a new class, the antagonists
of calcitonin gene-related peptide, will offer at least the same efficacy as that of potent triptans, but a
much better tolerability and no vascular contraindications. Concerning migraine prevention, news has
been concentrated on the management of chronic migraine, with the appearance of guidelines for
clinical trials in chronic migraine and the demonstration that it is a treatable entity, even in the
presence of overuse criteria.
Introduction and context
Migraine is a highly prevalent and disabling illness.
Globally, 11-13% of the adult population suffers from
active migraine. Optimal pharmacological treatment is
therefore crucial so the patient can have a reasonable
quality of life. Pharmacological treatment of migraine
includes acute symptomatic approaches, which are
needed by all migraineurs, as well as preventatives,
which should be prescribed in at least one-quarter of
migraine patients.
Recommended current symptomatic treatment of
migraine encompasses the judicious use of nonsteroidal
anti-inflammatory drugs (NSAIDs) and the 5-hydroxy-
tryptamine (5-HT1B/1D) selective receptor agonists
known as ‘triptans’. Simple/combined analgesics and
ergotamine-containing medications are not routinely
recommended in this indication because, compared with
NSAIDs and triptans, they are less efficacious, show a
poorer tolerability (ergotics), and are prone to induce
rebound headache and medication overuse [1]. At least
30% of migraine patients, however, either do not
respond or show contraindications (for example,
vascular risk factors) to the use of NSAIDs and/or
triptans. Migraine patients with one or more attack per
weekneedpreventivetreatmentand,inaddition,ifattacks
cause disability on 2 or more days per month and are
not prevented by optimized acute treatment, preventive
treatment is indicated if the patient is willing to take daily
medication [2,3]. Options with a demonstrated efficacy
in this indication include some beta-blockers, flunar-
izine, possibly low doses of amitriptyline, and the
antiepileptics valproic acid and topiramate. In line
with symptomatic treatment, no more than 60% of
migraine patients respond to and tolerate preventatives.
In conclusion, there is a need for better options for the
symptomatic and preventative treatment of migraine.
The most relevant recent advances for the management
of migraine are reviewed here.
Recent advances
Developments in acute treatment
As mentioned above, at least 30% of patients do not
respond to NSAIDs and/or triptans. How could the
efficacy of symptomatic treatment be improved? Of
course, an obvious approach is to explore nonoral routes
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5 mg or sumatriptan 20 mg) or even parenteral (for
example, subcutaneous sumatriptan or intramuscular/
intravenous NSAIDs) routes, which have demonstrated
a higher efficacy (but also a higher degree of adverse
events) in migraine patients refractory to the oral route.
As most migraine patients prefer the oral route, a few
treatment approaches have been tested to try to improve
the efficacy of current medications through this route [4].
Many trials have explored the efficacy of early treatment
of migraine attacks (when pain is still mild) with
triptans. In general, early treatment when pain was still
mild was numerically better as compared with late
treatment. The results of these trials, however, have been
very controversial because designs were not homoge-
neous, the advantage in terms of therapeutic gain was
not so clear, and early treatment could, at least
theoretically, induce medication overuse [5]. A recent
clinical trial has examined the efficacy of an oral triptan
(almotriptan 12.5 mg) in the treatment of migraine in
controlled conditions. This trial is interesting as, in the
early treatment arm, patients were asked to treat
migraine attacks when pain was still mild and by 1
hour of headache onset in order to test the Burstein
allodynia hypothesis (that is, 1 hour after the beginning
of migraine attack, allodynia develops and migraine
becomes intractable). Globally, the results of this clinical
trial suggest that treatment with almotriptan while
migraine is still mild provides a clinically relevant
enhancement in efficacy compared with treatment
when pain has reached higher severity levels. Interest-
ingly, the presence of allodynia did not correlate with
treatment response, which suggests that allodynia is just
one symptom associated with the migraine attack, such
as phono/photophobia, and not a specific marker for
response to acute treatment [6].
The second explored option to optimize acute migraine
treatment in refractory patients is the combination of
NSAIDs and triptans. A recent controlled trial with four
arms (placebo, naproxen 500 mg, sumatriptan 85 mg,
and both naproxen 500 mg plus sumatriptan 85 mg) has
shown interesting results with implications for clinical
practice [7] (Figure 1). First, the two active medications
were significantly more efficacious than placebo. Second,
for all efficacy endpoints, there was at least a numerical
advantage (not always significant) for sumatriptan as
compared with naproxen. Even though the dose of
naproxen could be considered too low for a fair
comparison, these data suggest some superiority of
triptans over NSAIDs (usually seen in clinical practice
but undemonstrated in serious clinical trials). Finally,
the combination of the two active medications was
clearly more efficacious than monotherapy. This indi-
cates that combining the two active medications with
different mechanisms of action translates in synergistic
actions.
In spite of early treatment and combination approaches,
there are still patients who do not respond or for whom
triptans cannot be administered due to the presence of
vascular contraindications, such as ischemic cardiomyo-
pathy. In the last year, the first results with an oral
compound of a totally new class of drug for the acute
treatment of migraine, the antagonists of the calcitonin
gene-related peptide (CGRP), have become available.
These drugs act through a novel mechanism by blocking
the action of CGRP on the CGRP receptor complex.
CGRP is released in the extracerebral circulation during
migraine attacks as a consequence of trigeminovascular
activation. The first oral CGRP antagonist, telcagepant,
has been shown to be as effective as two very efficacious
triptans, zolmitriptan 5 mg and rizatriptan 10 mg, for the
acute treatment of migraine. The rates for adverse events,
including chest symptoms, with telcagepant were com-
parable to those of placebo and lower than those seen for
the two active triptans [8-10].
Developments in preventive treatment
Preventive treatment of migraine is indicated in patients
with one or more attacks per week. Beta-blockers
continue to be the medication of choice for those
patients with migraine without aura attacks. Topiramate
has been extensively studied in this indication and is
now first in line for patients suffering from both
migraine with and without aura attacks, especially if
Figure 1. Summary of results of the controlled trial comparing
naproxen 500 mg, sumatriptan 85 mg, and the combination of
naproxen and sumatriptan
Note that each of the two medications as monotherapy is superior to
placebo, and note also the numerical advantage of sumatriptan 85 mg versus
naproxen 500 mg and the higher efficacy of the combination. Data are taken
from [7].
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have not responded or show contraindications to beta-
blockers. Flunarizine (available in some countries) or
valproate are indicated if both beta-blockers and
topiramate do not work. Not all antiepileptics work in
migraine prevention, as shown by a recent negative
double-blind controlled trial with oxcarbazepine [11].
In migraine prevention, the advances have been
concentrated in the field of chronic migraine (migraine
patients with headache more than 2 weeks per month).
These patients had been excluded from classical clinical
t r i a l s .T h i si si n c r e d i b l e ,a sp r e v a l e n c eo fc h r o n i c
migraine is 2% in the general population, and it
accounts for more than one-third of consultations in
headache clinics. Guidelines for clinical trials in chronic
migraine have recently been approved by the Interna-
tional Headache Society [12]. Very importantly, several
trials with topiramate and, in the preliminary stages,
with botulinum toxin have demonstrated that chronic
migraine patients are treatable, even in the presence of
analgesic overuse criteria [13-16] (Figure 2). In least in
half of the patients with frequent attacks, further trials
have shown that preventive treatment should be given
for periods clearly longer than 6 months [17,18].
Finally, the concept of combination therapy with beta-
blockers and topiramate in refractory patients looking
for a synergistic action (as mentioned above for acute
treatment) has also been explored with preliminary
positive results [19].
Implications for clinical practice
Implications for acute treatment
From the available results, it seems sensible to recom-
mend early treatment of attacks (as soon as the patient is
sure that he or she is having a migraine attack) with
triptans at least in those patients who do not show a clear
response when pain is already moderate or severe.
Preventive treatment must be considered in those
patients who exceed the maximum recommendation of
10 triptan days per month [1].
Research investigating the combination of NSAIDs and
triptans to optimize acute migraine treatment in
refractory patients has indicated that treatment from
the beginning of an attack with both an NSAID and a
triptan should be recommended for those patients who
do not exhibit a clear response with the two medications
in monotherapy.
A new class of drug, the antagonists of the CGRP, will
become available shortly as a new potential option for
patients who do not respond or on whom triptans
cannot be administered due to the presence of vascular
contraindications. As this new therapeutic class of drugs
is theoretically devoid of vasoconstrictor properties, they
could mark a new era in migraine treatment. Interest-
ingly, given the high potency of telcagepant, data from
dose-finding studies suggest that central actions are
necessary for the action of CGRP antagonists, which
would also change our mind regarding the mode of
action of acute antimigraine compounds [10].
Implications for preventive treatment
Beta-blockers continue to be the medication of choice to
prevent migraine in patients without aura attacks, and
the recent research into topiramate has indicated that it is
first in line for patients suffering from both migraine
with and without aura attacks, especially when they are
obese or where beta-blockers are not appropriate.
Extensive research on refractory patients suffering from
chronic migraine has been carried out over the last few
years. From a practical standpoint, the recent approval of
the guidelines for clinical trials in chronic migraine is
very important for the development of future manage-
ment strategies all over the world. Even though chronic
migraine remains a therapeutic challenge and overuse
prevention must continue to be a high priority, recent
work has shown that chronic migraine can be a treatable
condition, even in the presence of analgesic overuse, as
shown by the trials carried out with topiramate or
combining preventatives such as beta-blockers and
topiramate. There is hope that current trials and ongoing
research will continue to shed light on this area and
produce further clinical advances, such as the final
demonstration of a role for botulinum toxin type A in
the management of this condition.
Abbreviations
CGRP, calcitonin gene-related peptide; HT1B/1D, 5-
hydroxytryptamine 1B/1D; NSAID, nonsteroidal anti-
inflammatory drug.
Figure 2. Reduction in migraine frequency in patients with
chronic migraine with analgesic overuse
Data are taken from double-blind topiramate studies in [13-15].
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